# Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors

> **NCT07593092** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Xencor, Inc.** · enrollment: 90 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **BIOLOGICAL:** XmAb541
- **BIOLOGICAL:** XmAb808

## Key facts

- **NCT ID:** NCT07593092
- **Lead sponsor:** Xencor, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07593092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07593092, "Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors". Retrieved via AI Analytics 2026-08-15 from https://api.ai-analytics.org/clinical/NCT07593092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*